Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (111-120 of 222) with videos related to

Pageof 23
Sort By:
Cancer Research|September 23, 2018
Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate CancerJoshua W Russo, Ce Gao, Swati S Bhasin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2022
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancerWanting Han, Mingyu Liu, Dong Han, et al.
Cell Reports. Medicine|January 23, 2024
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancerJing Wang, Jing Wei, Tianjie Pu, et al.
Cell Reports|July 29, 2023
Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutationsSamantha L Schuster, Sonali Arora, Cynthia L Wladyka, et al.
Oncogene|January 3, 2023
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerJoy C Yang, Pengfei Xu, Shu Ning, et al.
The Journal of Pathology|August 25, 2021
Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancerKaushal Asrani, Alba Fc Torres, Juhyung Woo, et al.
The Journal of Clinical Investigation|June 2, 2020
Taxane resistance in prostate cancer is mediated by decreased drug-target engagementAda Gjyrezi, Fang Xie, Olga Voznesensky, et al.
British Journal of Cancer|October 5, 2023
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotypeMichelle Shen, Shiqin Liu, Angus Toland, et al.
Plos One|October 31, 2014
Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axisElahe A Mostaghel, Andrew Morgan, Xiaotun Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Pageof 23

Showing results (111-120 of 222) with videos related to

Sort By:
Pageof 23
Cancer Research|September 23, 2018
Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate CancerJoshua W Russo, Ce Gao, Swati S Bhasin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2022
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancerWanting Han, Mingyu Liu, Dong Han, et al.
Cell Reports. Medicine|January 23, 2024
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancerJing Wang, Jing Wei, Tianjie Pu, et al.
Cell Reports|July 29, 2023
Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutationsSamantha L Schuster, Sonali Arora, Cynthia L Wladyka, et al.
Oncogene|January 3, 2023
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerJoy C Yang, Pengfei Xu, Shu Ning, et al.
The Journal of Pathology|August 25, 2021
Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancerKaushal Asrani, Alba Fc Torres, Juhyung Woo, et al.
The Journal of Clinical Investigation|June 2, 2020
Taxane resistance in prostate cancer is mediated by decreased drug-target engagementAda Gjyrezi, Fang Xie, Olga Voznesensky, et al.
British Journal of Cancer|October 5, 2023
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotypeMichelle Shen, Shiqin Liu, Angus Toland, et al.
Plos One|October 31, 2014
Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axisElahe A Mostaghel, Andrew Morgan, Xiaotun Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Pageof 23